DUBAI: A leading scientist from Harvard University has announced what he describes as a major breakthrough in the fight against aging, claiming that biological aging could soon be reversed rather than merely managed.
Speaking at the 2026 Dubai Summit, Dr. David Sinclair characterized aging as a treatable medical condition rather than an unavoidable part of life. He predicted that advances in biotechnology could render much of modern healthcare obsolete within the next 10 to 20 years by shifting the focus from symptom management to the full reversal of biological aging.
According to Sinclair, his research team has achieved up to a 75 percent reversal of aging markers in animal studies through partial epigenetic reprogramming.
The process involves modified versions of the Shinya Yamanaka genes, widely known as Yamanaka factors, which are linked to cellular rejuvenation. In experimental models, the technique has also restored vision in animals suffering from blindness-related conditions.
“Scientists have found ways to ‘polish’ the biological system and restore cellular function,” Sinclair said, emphasizing that cells can be reprogrammed to regain youthful characteristics without losing their identity.
The research team is now preparing for human clinical trials aimed at reversing specific aspects of aging. These trials will test epigenetic programming therapies designed to reset cells to a younger biological state.
“We are about to test, for the first time in history, whether we can reverse aging and cure diseases,” he stated.
Beyond medical implications, Sinclair highlighted the potential economic impact of anti-aging breakthroughs.
He noted that in the United States alone, extending healthy lifespan by just one year could generate an estimated $38 trillion in economic value by boosting productivity.
He also linked his findings to global demographic challenges, including declining fertility and falling birth rates. Sinclair argued that societies may soon face a choice between replacing workers with automation or keeping people healthier and productive for longer periods.
“Our greatest asset is human productivity,” he said.
While the trials are expected to begin soon, specific dates and detailed protocols have not yet been disclosed.
